ERBB2 and breast carcinoma: In the appraisal of trastuzumab emtansine for adjuvant treatment of HER2-positive early breast cancer (TA632), the primary clinical evidence, KATHERINE trial, recruited 1486 patients randomised 1:1 to intervention and comparators.